Michelle McBane

Managing Director

2017 - Current

StandUp Ventures is a seed-stage fund investing across Canada in female-led or co-led high growth ventures. Since inception, we've made 15 investments in B2B enterprise software and digital health companies. Portfolio companies include tealbook, Coconut Software, Bridgit, emovi, Nudge, ODAIA, StoryTap, MiMS, Sampler, Amacathera, Arteria, Disco, Acerta & Aya Payments. www.standupvc.com

Board Member

2017

Part time Instructor

2014 - 2021

Instructor teaching entrepreneurship curriculum including "Identifying Opportunities" - a course based on the lean startup methodology.

Senior Investment Director

2010 - 2019

All aspects of leading seed venture investment including deal sourcing, due diligence, term negotiation, legal diligence, closing and on-going involvement typically as an observer on the board of directors. Led, co-led or participated in investments in more than 20 early-stage opportunities. Select current portfolio includes Sampler (www.sampler.io), OMX (www.theomx.com), Opencare (www.opencare.com), Magniware, Figure1 (www.figure1.com), Rubikloud (www.rubikloud.com), Xagenic (www.xagenic.com), Profound Medical (www.profoundmedical.com) and several others. Past exits include Cytochroma (acquired by OPKO) and Locationary (acquired by Apple).

Principal

2008 - 2010

Consulting to the venture capital industry including fund managers and venture-backed companies. Recent projects include team member which developed a business and execution plan for the launch of a social venture fund and the development of a commercialization plan for a specialty pharma company.

Investment team

2003 - 2008

As a member of the Advanced Life Science Investment Fund responsibilities include: *All aspects of venture investing; deal flow generation and analysis, valuation, due diligence, forming syndicates, leading investments and exit planning. Invested in early to late stage companies in the areas of therapeutics, and medical devices and diagnostic tools *Deal flow generation through established networks including North American venture capital community. *Value adding investor post-investment through observer role on board and development of relationship with senior management. *Board Observer on Cytochroma, Interface Biologics, Axela Inc., Z-Tech Medical and Xceed Molecular Inc.

Investment team

2001 - 2003

Marketing Manager

1989 - 2001